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irinotecan dose escalation to treat 70 mCRC patients. The UGT1A1 *1/*1 and *1/*28 genotypes started with a 180-
mg/m2 dose of irinotecan, and UGT1A1 *28/*28 genotype started with a dose of 120 mg/m2. The dose of
irinotecan was escalated at increasing intervals of 20 to 30 mg/m2 until grade 3/4 adverse events (AEs) occurred.
The clinical response rate, toxicity, and survival were analyzed. RESULTS: The clinical response and disease control
rates of mCRC patients treated with FOLFIRI plus bevacizumab were significantly better in patients with UGT1A1
*1/*1 and *1/*28 genotypes than in patients with UGT1A1 *28/*28 (P = .006 and P b .001, respectively). Grade 3/4
AEs were significantly more common in mCRC patients with the UGT1A1 *28/*28 genotype (P b .001).
Progression-free survival was significantly higher in UGT1A1 *1/*1 and *1/*28 patients (P = .002). mCRC patients
who underwent metastasectomy achieved better overall survival than those who did not undergo metastasectomy
(P = .015). CONCLUSIONS: Our study showed that mCRC patients with UGT1A1 *1/*1 and *1/*28 genotypes
could receive escalated doses of irinotecan to obtain a more favorable clinical outcome without significant AEs.
Translational Oncology (2015) 8, 474–479Introduction
Colorectal cancer (CRC) is the third most common cause of
cancer-related mortality worldwide, with over 1.2 million new cancer
cases and 608,700 deaths estimated to have occurred in 2008 [1].
Almost all metastatic CRC (mCRC) patients require systemic
treatment to palliate symptoms or downstage tumor status to be
eligible for further surgical intervention or metastasectomy. In the
past 40 years, 5-fluorouracil (5-FU) has been widely used as an
effective chemotherapeutic agent in the treatment of advanced CRC.
In the early 1980s, 5-FU combined with leucovorin (LV) was found
to increase tumor response rate and the length of time to progression.
New drugs such as irinotecan and oxaliplatin in various
combinations with 5-FU/LV have further improved the outcome in
many advanced CRC patients [2]. Infusional 5-FU/LV plus
irinotecan (FOLFIRI) has emerged as a standard first-line therapeutic
option for mCRC patients. Irinotecan is a prodrug that is converted
to an active form, 7-ethyl-10-hydroxycamptothecin (SN-38), in vivo
where it elicits cytotoxicity via potent inhibition of topoisomerase I.
SN-38 is further detoxicated into its inactive metabolite, SN-38G,
through glucuronidation by the enzyme uridine diphosphate
glucuronosyltransferase (UGT) in the liver [3]. The glucuronidation
of SN-38 to SN-38G is a decisive step in the metabolism and
detoxification of irinotecan. However, genetic polymorphisms of the
UGT1A1 can alter the glucuronidation of SN-38 and as such have a
major influence on the pharmacokinetics and toxicity of irinotecan
[4]. The number of repeats of TATA box in the UGT1A1 promoter
alters UGT1A1 activity [5], with 6TA repeats representing the most
common allele of UGT1A1 gene (UGT1A1*1, wild type) and 7TA
repeats representing a variant allele (UGT1A1*28, mutant type).
Reduced UGT1A1 expression is found in individuals with the
UGT1A1*28 variant, and consequently reduced SN-38 glucuronida-
tion and increased irinotecan-related toxicity are well established in
patients with this genotype [6].
The recommended dose of irinotecan in FOLFIRI regimen is 180
mg/m2 every 2 weeks. However, this dose is insufficient in patients
with the UGT1A1*1 allele and contributes to a poorer clinical
outcome [7–10]. Conversely, 180 mg/m2 of irinotecan in patients
with homozygous UGT1A1*28 is associated with a greater number of
severe adverse events (AEs) [7,11]. Increase in the irinotecan dose in abid to improve the response rate increases the risk of AEs such as
neutropenia and diarrhea. To date, the appropriate irinotecan dosage
modifications for patients with UGT1A1*1 and UGT1A1*28 alleles
are not clearly defined.
Recently, the therapeutic regimen for mCRC has been altered with
the introduction of biologic drugs such as bevacizumab and
cetuximab [12,13]. These 2 biologic agents targeting either the
vascular endothelial growth factor (bevacizumab) or epidermal
growth factor receptor (cetuximab) have been incorporated into
previous irinotecan or oxaliplatin-backbone 5-FU/LV chemothera-
peutic regimens as first-line intensive therapy for potentially
resectable or aggressive tumors [14].
Our study aimed to identify the role of UGT1A1 gene
polymorphisms in the efficacy and safety of irinotecan dose escalation
in mCRC patients treated with FOLFIRI plus bevacizumab as the
first-line setting.
Materials and Methods
Patients
Between June 2009 and October 2012, 70 mCRC patients in the
Kaohsiung Medical University Hospital were enrolled according to a
retrospective review of medical charts. UGT1A1 genotyping was
performed on all patients before initiating bevacizumab plus
FOLFIRI chemotherapy. The starting dose of irinotecan depended
on the genotyping results and was escalated at increasing intervals
of 20 to 30 mg/m2 until grade 3/4 AEs occurred. The 70 patients
were divided into 2 groups according to UGT1A1 genotypes. All
patients were stage IV mCRC and unrelated ethnic Chinese residing
in Taiwan.
Eligibility Criteria
mCRC patients with histologically or radiologically proven
metastatic lesions were eligible for this study. Eligibility criteria also
included sufficient renal, hepatic, and bone marrow function; an
Eastern Cooperative Oncology Group performance status of 0 to 2;
no central nervous system metastases; no uncontrolled or serious
concurrent medical illnesses; no active infections; no other primary
malignancies; age N 18 years; and life expectancy N 3 months. All of
Table 1. Clinicopathologic Features of 70 Metastatic Colorectal Cancer Patients Receiving
FOLFIRI Plus Bevacizumab Chemotherapy
Variables Number (%)
Gender
Male/female 42 (60.0)/28 (40.0)
Age (years) (mean ± SD) 69.0 ± 12.3
Maximum tumor size (cm)
b5/≥5 42 (60.0)/28 (40.0)
Location
Colon/rectum 51 (72.9)/19 (27.1)
Depth of invasion
T1+T2/T3+T4 7 (10.0)/63 (90.0)
Lymph node metastasis
N(−)/N(+) 12 (17.1)/58 (82.9)
Vascular invasion
Yes/no 25 (35.7)/45 (64.3)
Perineural invasion
Yes/no 44 (62.9)/26 (37.1)
Histology
WD/MD/PD 6 (8.6)/54 (77.1)/10 (14.3)
Response
CR+PR/SD+PD 51 (72.9)/19 (27.1)
Disease control rate
CR+PR+SD/PD 63 (90.0)/7 (10.0)
Metastasectomy
Yes/no 18 (25.7)/52 (74.3)
AE grade 3/4
Yes/no 7 (10.0)/63 (90.0)
WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated.
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bilirubin level. Patients with other malignant diseases in their medical
history were excluded.
Groups and Treatment
Group 1 included patients with the UGT1A1 *1/*1 and *1/*28
genotype. Group 2 included patients with the UGT1A1 *28/*28
genotype. According to our previous reports [15,16], the treatment
regimen comprised bevacizumab (Avastin, Roche Pharmaceuticals,
Basel, Switzerland) (5 mg/kg; 120-minute IV infusion) on day 1,
followed by irinotecan (starting dose: 180 mg/m2 for group 1 and
120 mg/m2 for group 2; 120-minute IV infusion), LV (200 mg/m2;
IV infusion over 2 hours), and 5-FU (400 mg/m2; IV bolus infusion
followed by 2400-mg/m2 IV infusion over 46 hourrs), every 2 weeks.
The maximal administration dose of irinotecan will be 260, 240, and
210 mg/m2 for UGT1A1 *1/*1, *1/*28, and *28/*28 genotype.
After the first two treatment cycles, hematological and nonhema-
tological AEs (including neutropenia, diarrhea and nausea/vomiting
etc.) were assessed. The severity of adverse effects was evaluated
according to the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0 (http://ctep.cancer.gov/
reporting/ctc.html; accessed in October 2015). If AEs were of less
than grade 3, we gradually escalated the dose by 20 to 30 mg/m2
every 2 cycles. Dose escalation was stopped if grade 3 or 4 AEs
occurred, and when such grade 3/4 AEs did occur, the patients were
subsequently treated with the highest dose of irinotecan that they
were previously able to tolerate.
Genotyping
Constitutional gene polymorphisms were analyzed by DNA
extraction from 4 ml of peripheral blood using PUREGENE DNA
Isolation Kit (Gentra Systems Inc., Minneapolis, MN, USA). All
genomic DNA from the patients were analyzed using direct
sequencing to determine the UGT1A1 promoter region genotype.
Primers used in this study were designed using primer 3 free software
(http://primer3.wi.mit.edu). The sequences of the forward and
reverse primers were 5 -AGTCACGTGACACAGTCAAACA-3
and 5 -CTTTGCTCCTGCCAGAGGTT-3 , respectively. The
PCR volume was 40 μl, and the PCR conditions were as follows:
94°C for 5 minutes; 30 cycles of denaturation for 30 seconds at 94°C,
annealing for 20 seconds at 67.5°C, and primer extension for
20 seconds at 72°C; and final extension for 10 minutes at
72°C. Genotypes were verified by fragment analysis of the
PCR product using the automated capillary electrophoresis on the
ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA) and analyzed using GeneScan and Genotyper software
(Applied Biosystems).
Postchemotherapeutic Surveillance
The response to treatment was assessed radiologically by computed
tomography, magnetic resonance imaging, or positron emission
tomography, and the best response was recorded. The first response
assessment was usually after the fourth or sixth cycle in patients who
received bevacizumab combined with FOLFIRI chemotherapy.
Patients’ responses were classified according to the Response
Evaluation Criteria in Solid Tumors (version 1.1) [17]. Complete
response (CR) was defined as the disappearance of all target lesions;
partial response (PR) was defined as at least a 30% decrease in the
sum of the longest diameter from baseline. Progressive disease (PD)was defined as at least a 20% increase in the sum of the longest
diameter of target lesions, with the smallest sum of the longest
diameters recorded before treatment as reference. PD was also defined
as the identification of one or more new lesions. Stable disease (SD)
was defined as neither sufficient shrinkage to quality for PR nor
sufficient increase to qualify for PD. The best response was defined as
the best result recorded by the investigators because the confirmatory
imaging evidence of response obtained after four to six cycles of
chemotherapy was not consistently available. The median follow-up
period was 22 months (range, 6-34 months). This study conformed
to the Helsinki Declaration and was approved by the Institutional
Review Board of Kaohsiung Medical University Hospital. The
written informed consents were collected from all participated
patients. For liver/lung metastatic lesions, metastasectomy was
performed after a multidisciplinary team meeting. The primary end
points were response rate and progression-free survival (PFS); the
secondary endpoints were toxicity and overall survival (OS).
Statistical Analysis
All data were analyzed using Statistical Package for Social
Sciences, Version 14.0, software (SPSS Inc., Chicago, IL, USA).
A P value of b .05 was considered statistically significant. Univariate
analysis of clinicopathologic features between the two groups (6/6
and 6/7 group vs 7/7 group) was compared using the Pearson
chi-square or Fisher exact t test. PFS was defined as the time from the
beginning of chemotherapy until the first documentation of
progression regardless of the patient’s treatment status. OS was
defined as the time between the beginning of chemotherapy and
death from any cause. PFS and OS rates were calculated using the
Kaplan-Meier method, and the differences in survival rates were
analyzed using the log-rank test. A probability of less than .05 was
considered statistically significant.
Table 2. Correlation between Different UGT1A1 Genotypes and Clinicopathologic Features by
Univariate Analysis
Genotype *1/*1 and
*1/*28 (N = 65) (%)
Genotype *28/*28
(N = 5) (%)
P a
Gender
Male/female 39 (60.0)/26 (40.0) 3 (60.0)/2 (40.0) 1.000
Age (years)
b70/≥70 15 (23.1)/50 (76.9) 1 (20.0)/4 (80.0) .875
Maximum size (cm)
b5/≥5 38 (58.5)/27 (41.5) 4 (80.0)/1 (20.0) .343
Location
Colon/rectum 48 (73.8)/17 (26.2) 3 (60.0)/2 (40.0) .502
Depth of invasion
T1 + T2/T3 + T4 6 (9.2)/59 (90.8) 1 (20.0)/4 (80.0) .360
Lymph node metastasis
N(−)/N(+) 11 (16.9)/54 (83.1) 1 (20.0)/4 (80.0) .886
Vascular invasion
Yes/no 25 (38.5)/40 (61.5) 0 (0.0)/5 (100.0) .097
Perineural invasion
Yes/no 40 (61.5)/25 (38.5) 4 (80.0)/1 (20.0) .457
Histology
WD/MD/PD 6 (9.2)/49 (75.4)/10 (15.4) 0 (0.0)/5 (100.0)/0 (0.0) .528
Response
CR+PR/SD+PD 50 (76.9)/15 (23.1) 1 (20.0)/4 (80.0) .006
Disease control rate
CR+PR+SD/PD 61 (93.8)/4 (6.2) 2 (40.0)/3 (60.0) b .001
AE grade 3/4
Yes/no 4 (6.2)/61 (93.8) 3 (60.0)/2 (40.0) b .001
a Chi-square test.
Table 4. UGT1A1 Genotyping and Response in mCRC Patients Treated with FOLFIRI and
Bevacizumab
UGT1A1 Genotype N (%)
Response *1/*1 &*1/*28 *28/*28 Total P
CR 2 (3.1%) 0 (0%) 2 (2.9%) .001
PR 48 (73.8%) 1 (20.0%) 49 (70.0%)
SD 11 (16.9%) 1 (20.0%) 12 (17.1%)
PD 4 (6.2%) 3 (60.0%) 7 (10.0%)
Total 65 (100%) 5 (100%) 70 (100%)
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The average age of the patients was 69.0 years (range, 40-78 years;
Table 1). Fifty-one patients presented with colon cancer (72.9%) and
19 with rectal cancer (27.1%). Analysis of histological type showed
that 6 (8.6%) of the tumors were well differentiated, 54 (77.1%) were
moderately differentiated, and 10 (14.3%) were poorly differentiated.
With regard to clinicopathologic features, 25 (35.7%) patients had
vascular invasion and 44 (62.9%) had perineural invasion. The
response and disease control rates were 72.9% (51/70) and 90% (63/
70), respectively. Eighteen mCRC patients (25.7%) were suitable for
metastasectomy after initial bevacizumab plus FOLFIRI chemother-
apy. Grade 3/4 AEs occurred in 7 mCRC patients (10%). Table 2
shows the correlation between UGT1A1 genotypes and clinicopath-
ologic features of the 70 mCRC patients receiving bevacizumab plus
FOLFIRI. On univariate analysis, the clinical response and disease
control rates were significantly higher in the UGT1A1 *1/*1 and
*1/*28 group than in the *28/*28 group (P = .006 and P b .001,
respectively). Grade 3/4 AEs were significantly less frequent in
the UGT1A1 *1/*1 and *1/*28 group than in the *28/*28 group
(P b .001).Table 3. UGT1A1 Genotyping and Maximal Tolerated Dose of Irinotecan in mCRC Patients
Treated with FOLFIRI and Bevacizumab
UGT1A1 Genotype N (%)
Irinotecan Dosage *1/*1 & *1/*28 *28/*28 Total P
120 mg/m2 0 (0%) 2 (40.0%) 2 (2.9%) b .001
150 mg/m2 1 (1.5%) 1 (20.0%) 2 (2.9%)
180 mg/m2 26 (40.0%) 1 (20.0%) 27 (38.6%)
210 mg/m2 22 (33.8%) 1 (20.0%) 23 (32.9%)
240 mg/m2 11 (16.9%) 0 (0%) 11 (15.7%)
260 mg/m2 5 (7.7%) 0 (0%) 5 (7.1%)
Total 65 (100%) 5 (100%) 70 (100%)Table 3 shows the different maximal doses of irinotecan tolerated
by mCRC patients with variant UGT1A1 genotypes. The UGT1A1
*1/*1 and *1/*28 group started with a 180-mg/m2 dose of irinotecan,
which was progressively escalated up to 260 and 240 mg/m2,
respectively. The UGT1A1 *28/*28 group started with a dose of 120
mg/m2, but this was progressively escalated up to only 210 mg/m2 in
only 1 patient. In addition, 58.4% of patients with the UGT1A1 *1/
*1 and *1/*28 genotypes were able to tolerate a maximal irinotecan
dose greater than the recommended 180-mg/m2 dose, but only 1
patient with the UGT1A1 *28/*28 genotype (20%) was able to
tolerate a dose of N180 mg/m2 (P b .001, Table 3). However, 1
patient with the UGT1A1 *1/*1 genotype experienced a grade 3 AE,
and therefore, the irinotecan dose was reduced to 150 mg/m2.
Table 4 shows variant UGT1A1 genotypes of mCRC patients and
their different clinical response rates to bevacizumab and FOLFIRI.
Patients with UGT1A1 *1/*1 and *1/*28 genotypes showed a
response rate of 76.9%, compared with a response rate of 20% in
patients with the UGT1A1 *28/*28 genotype (P = .001, Table 4).
Moreover, grade 3/4 AEs were more common among patients with
the UGT1A1 7/7 genotype than among those with the UGT1A1 *1/
*1 and *1/*28 genotypes (P b .001, Table 2). However, patients older
than 70 years did not show significantly increased rates of grade 3/4
AEs (P = .569, Table 5).
PFS was significantly different for the different UGT1A1
genotypes (P = .002, Figure 1A). Furthermore, the possibility of
metastasectomy significantly influenced OS in mCRC patients after
bevacizumab plus FOLFIRI chemotherapy (P = .015, Figure 1B).
Discussion
Several trials have used bevacizumab in diverse combinations with
irinotecan- or oxaliplatin-based 5-FU/LV regimens as first-line
treatment for mCRC, but the results are inconsistent for different
regimens [18]. These divergent results can be partially explained by
pharmacogenetic studies that have shown that UGT1A1 genetic
polymorphisms can result in inefficient irinotecan metabolism.
Genotyping of mCRC patients therefore represents an opportunity
to enhance the efficacy of irinotecan treatment. We can use individual
genotype analysis to predict the severity of irinotecan toxicities and
increase the dose of irinotecan to as high levels as are tolerable to
achieve maximal benefit for tumor treatment. In this study,Table 5. Age and Grade 3/4 AEs in mCRC Patients Treated with FOLFIRI and Bevacizumab
AE Grade 3/4 P
Yes No
Age N70 6 (11.1%) 48 (88.9%)
b70 1 (6.3%) 15 (93.8%) .569
Figure 1. (A) Progression-free survival according to the UGT1A1
genotype (P = .002); 6/6, 6/7, and 7/7 means *1/*1, *1/*28, and
*28/*28 genotype, respectively. (B) Overall survival in mCRC
patients with or without metastasectomy (P = .015).
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*28 genotypes were able to tolerate irinotecan doses greater than the
recommended dose of 180 mg/m2 (Table 3). By using genotyping as
a guide, patient-specific irinotecan dose optimization represents a way
of individualizing cancer therapy [19].
Among newly diagnosed CRC cases, 20% to 25% present with
metastatic disease [20,21]. Surgical resection of metastatic lesions
offers a potentially curative approach for CRC patients with locally
confined metastases. For mCRC patients with initially unresectable
lesions, neoadjuvant chemotherapy combined with targeted agents is
favored to downstage disease status to be resectable and improve
survival. Reported resectability rates after chemotherapy plus
bevacizumab vary widely from 11.8% (225/1914) [22] to 51%
(61/120) [23] in different studies [24]. Discrepancies among these
studies are attributed to selected chemotherapeutic regimens and
study designs, making comparison difficult. Our study demonstrates
that the FOLFIRI plus bevacizumab regimen can downstage initiallyunresectable metastases to resectable disease in 18 of 70 (25.7%)
mCRC patients (Table 1). Furthermore, mCRC patients undergoing
metastasectomy show significantly improved survival compared with
patients without metastasectomy (P = .015).
This study evaluated the dose-limited toxicity and maximal
tolerated dose of irinotecan in the FOLFIRI plus bevacizumab
regimen, which was used as the first-line treatment for mCRC
according to UGT1A1 genotypes. In this dose-escalating trial, we
have demonstrated that the recommended dose of 180 mg/m2 for
irinotecan is considerably lower than the dose that can be tolerated by
patients with the UGT1A1 *1/*1 and *1/*28 genotypes. In fact, some
of our patients with UGT1A1 *1/*1 and *1/*28 genotypes can safely
tolerate the dose of irinotecan up to 260 and 240 mg/m2,
respectively. Our results are consistent with those of previous studies
that used the FOLFIRI regimen to treat mCRC patients with
irinotecan dose escalation according to UGT1A1 genotypes [7,8]. For
patients with the UGT1A1 *28/*28 genotype, the starting dose of
irinotecan should be decreased to diminish the AEs of irinotecan.
Stratification of mCRC patients according to genotype results in a
significantly higher response rate and PFS in patients with UGT1A1
*1/*1 and *1/*28 genotypes compared with patients with the
UGT1A1 *28/*28 genotype. In addition, a response rate was
achieved in only 20% of mCRC patients with the UGT1A1 *28/*28
genotype who received FOLFIRI plus bevacizumab therapy.
Therefore, it is necessary to consider alternative, more active
chemotherapeutic regimens for this subgroup of patients.
Published reports have demonstrated the irinotecan dose-
associated toxicities in patients with UGT1A1*28 genotype [25–27].
The U.S. Food and Drug Administration in 2005 approved the
identification of UGT1A1*28 homozygous patients that were
recommended with a lower dose of irinotecan administration [28].
Also, the Evaluation ofGenomic Application in Practice and Prevention
working group has indicated that UGT1A1*28 genotyping will be only
clinically useful on the aspect of safety use of irinotecan without
compromising the efficacy of this drug [29]. Nevertheless, reduction of
dosage might also be associated with reduced tumor therapeutic
response and/or increased mortality. The study of Shulman et al. has
showed that UGT1A1*28 genotype is strongly associated with severe
hematologic toxicity and lower survival of CRC patients in use of
irinotecan [30]. Whereas most reports concerning the pretherapeutic
check of UGT1A1*28 genotype are for consideration of AEs, our
present study emphasizes the encouraging detection of UGT1A1*1
genotype to escalate the dose of irinotecan to achieve the maximal
therapeutic effect. Furthermore, the role of irinotecan dose escalation is
especially important in Asian races because they inherit more frequency
of UGT1A1*1 allele than Caucasians [9,11].
Besides UGT1A1*28, there are many ethnic differences and
frequencies in UGT1A gene, some of which were also reported to
influence the efficacy and toxicity of irinotecan via similar interfering
hepatic metabolism. Takano et al. [31] reported that the UGT1A1*6
polymorphism is a potential predictor of severe neutropenia derived
by irinotecan in Japanese patients. Hazama et al. [32] reported that
assessment of UGT1A1*28 and *6 and also UGT1A7*3 and
UGT1A9*22 is very important to predict the toxicity of irinotecan
in Japanese patients. Hence, the relative contribution of variant
UGT1A gene polymorphisms to the prediction of the outcome of
FOLFIRI therapy in patients of different races should be determined
in the future researches. A limitation of our study is that it is
hypothesis generating because of the retrospective design and
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numbers of patients would be planned to confirm our results.
In summary, our findings show that mCRC patients with
UGT1A1 *1/*1 and *1/*28 genotypes can tolerate a higher dose of
irinotecan to achieve a more favorable therapeutic response while
using the FOLFIRI plus bevacizumab regimen. mCRC patients with
the UGT1A1 *28/*28 genotype show poorer response with
irinotecan-based chemotherapy and may benefit from alternative
therapeutic regimens.
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